CDK4 and neoplasm: While targeting CDK6 can directly inhibit tumor cell proliferation, we put forward a pathway by which blocking CDK4 and CDK6 in cancer cells enhance anti-tumor immune responses by inducing DNA damage-mediated, STING-dependent type I IFN production (Fig. 8e).